Stock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts

Stock Track03-02

Sarepta Therapeutics (SRPT) stock plummeted 5.01% during intraday trading on Monday, reflecting significant negative sentiment among investors.

The sharp decline follows analyst actions that reduced optimism for the stock. Wedbush analyst Yun Zhong lowered the firm's price target on Sarepta to $29 from $34, though maintained an Outperform rating. Additionally, HC Wainwright & Co. maintained its price target at $5.00 per share, a level substantially below current trading prices, which may have contributed to the bearish pressure.

These analyst adjustments suggest concerns about the company's valuation or future prospects, leading to the sell-off in the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193204299?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193204299","market":"sg","top_or_hot":-1,"title":"Stock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts","media":"Stock Track","content":"<p>Sarepta Therapeutics (SRPT) stock plummeted 5.01% during intraday trading on Monday, reflecting significant negative sentiment among investors.</p><p>The sharp decline follows analyst actions that reduced optimism for the stock. Wedbush analyst Yun Zhong lowered the firm's price target on Sarepta to $29 from $34, though maintained an Outperform rating. Additionally, HC Wainwright & Co. maintained its price target at $5.00 per share, a level substantially below current trading prices, which may have contributed to the bearish pressure.</p><p>These analyst adjustments suggest concerns about the company's valuation or future prospects, leading to the sell-off in the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sarepta Therapeutics Plummets 5.01% Intraday on Analyst Price Target Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sarepta Therapeutics (SRPT) stock plummeted 5.01% during intraday trading on Monday, reflecting significant negative sentiment among investors.</p><p>The sharp decline follows analyst actions that reduced optimism for the stock. Wedbush analyst Yun Zhong lowered the firm's price target on Sarepta to $29 from $34, though maintained an Outperform rating. Additionally, HC Wainwright & Co. maintained its price target at $5.00 per share, a level substantially below current trading prices, which may have contributed to the bearish pressure.</p><p>These analyst adjustments suggest concerns about the company's valuation or future prospects, leading to the sell-off in the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPT","symbol_name":"Sarepta Therapeutics","start_time":0,"source_url":"","article_id":"1193204299","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193204299","pubTimestamp":1772463680,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Sarepta Therapeutics (SRPT) stock plummeted 5.01% during intraday trading on Monday, reflecting significant negative sentiment among investors.The sharp decline follows analyst actions that reduced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRPT":"Sarepta Therapeutics"},"translate_title":"个股追踪|分析师下调目标价Sarepta Therapeutics盘中暴跌5.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Sarepta Therapeutics (SRPT) stock plummeted 5.01% during intraday trading on Monday, reflecting significant negative sentiment among investors.The sharp decline follows analyst actions that reduced optimism for the stock. Wedbush analyst Yun Zhong lowered the firm's price target on Sarepta to $29 from $34, though maintained an Outperform rating. Additionally, HC Wainwright & Co. maintained its price target at $5.00 per share, a level substantially below current trading prices, which may have contributed to the bearish pressure.These analyst adjustments suggest concerns about the company's valuation or future prospects, leading to the sell-off in the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193204299","isCrawlerRequest":true}